Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model

Gier, Belinda, Matveyenko, Aleksey V., Kirakossian, David, Dawson, David, Dry, Sarah M., Butler, Peter C.·2012·Diabetes

DOI 10.2337/db11-1109

Cited by (256)

Items 101–200 of 256

Antihyperglycaemic therapies and cancer risk
Stefan Z Lutz, Harald Staiger, Andreas Fritsche, Hans‐Ulrich Häring · 2014 · Diabetes and Vascular Disease Research
Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes
Allison L. Brill, Jaclyn A. Wisinski, Mark T. Cadena, Mary F. Thompson, Rachel J. Fenske, Harpreet K. Brar, Michael D. Schaid, Renee L. Pasker, Michelle E. Kimple · 2016 · Molecular Endocrinology
A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
Stefano Genovese, Edoardo Mannucci, Antonio Ceriello · 2017 · Advances in Therapy
Vascular Complications of Diabetes Mellitus
Yien Chiong, Carmella Evans‐Molina · 2014 · Springer eBooks
The double trouble of metabolic diseases: the diabetes–cancer link
Slavica Tudzarova, Mahasin A. Osman · 2015 · Molecular Biology of the Cell
Immunohistochemical assessment of glucagon‐like peptide 1 receptor ( GLP‐1R ) expression in the pancreas of patients with type 2 diabetes
Rikke Kaae Kirk, Charles Pyke, Matthias G. von Herrath, Jane Preuss Hasselby, Lars Pedersen, Pia G. Mortensen, Lotte Bjerre Knudsen, Ken T. Coppieters · 2017 · Diabetes Obesity and Metabolism
Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes
Belinda Schludi, Abu Saleh Md Moin, Chiara Montemurro, Tatyana Gurlo, Aleksey V. Matveyenko, David Kirakossian, David W. Dawson, Sarah Dry, Peter C. Butler, Alexandra E. Butler · 2017 · JCI Insight
Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition
Elisabeth Streckel, Christina Braun-Reichhart, Nadja Herbach, Maik Dahlhoff, Barbara Keßler, Andreas Blutke, Andrea Bähr, Nicole Übel, Matthias Eddicks, Mathias Ritzmann et al. · 2015 · Journal of Translational Medicine
Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?
Benjamin J. Lamont, Sofianos Andrikopoulos · 2014 · Journal of Endocrinology
Beneficial long‐term antidiabetic actions of N ‐ and C ‐terminally modified analogues of apelin‐13 in diet‐induced obese diabetic mice
Vadivel Parthsarathy, Christopher Hogg, Peter R. Flatt, Finbarr P.M. O'Harte · 2017 · Diabetes Obesity and Metabolism
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, Gerald H · 2014 · World Journal of Diabetes
Challenges of Managing Type 3c Diabetes in the Context of Pancreatic Resection, Cancer and Trauma
Colton D. Wayne, Chahrazed Benbetka, Gail Ellen Besner, Siddharth Narayanan · 2024 · Journal of Clinical Medicine
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis
Mark Ayoub, Rafi Aibani, Tiana M. Dodd, Muhammed Murtada Ceesay, Muhammad Mujtaba Bhinder, Carol Faris, Nisar A. Amin, Ebubekir S. Daglilar · 2024 · Cancers
Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review
Xia Nan Guo, Qing Yang, Jianjun Dong, Lin Liao, Weiwei Zhang, Fupeng Liu · 2016 · Clinical Drug Investigation
Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan
Chao‐Ming Tseng, Wei‐Chih Liao, Chi‐Yang Chang, Ching‐Tai Lee, Cheng‐Hao Tseng, Yao‐Chun Hsu, Jaw‐Town Lin · 2016 · Pancreatology
Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Louis Monnier, C Colette, David R. Owens · 2013 · Diabetes & Metabolism
Expression of Glucagon-Like Peptide 1 Receptor and its Effects on Biologic Behavior in Pancreatic Neuroendocrine Tumors
Ana Inés Cases, Takao Ohtsuka, Minoru Fujino, Noboru Ideno, Shingo Kozono, Ming Zhao, Kenoki Ohuchida, Shinichi Aishima, Masatoshi Nomura, Yoshinao Oda et al. · 2013 · Pancreas
Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet‐induced obese diabetic mice
Finbarr P.M. O'Harte, MT Ng, Angela M. Lynch, John Michael Conlon, Peter R. Flatt · 2016 · Diabetes Obesity and Metabolism
Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention
Tooba Laeeq, Maheen Ahmed, Hina Sattar, Muhammad Hamayl Zeeshan, Meher Binte Ali · 2024 · Cancers
Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan
Hsien‐Yen Chang, Chi-Feng Hsieh, Sonal Singh, Wenze Tang, Yi-Ting Chiang, Weng-Foung Huang · 2015 · Pharmacoepidemiology and Drug Safety
A pooled analysis of exenatide use and risk of acute pancreatitis
David D. Dore, Mohamed Hussein, Clorinda Hoffman, Elise M. Pelletier, Daniel B. Smith, John D. Seeger · 2013 · Current Medical Research and Opinion
Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation and Ductal Hyperplasia in Non-Human Primates
Teresa Vanessa Fiorentino, Michael A. Owston, GREGORY A. ABRAHAMIAN, Stefano La Rosa, Alessandro Marando, Carla Perego, E.S. Di Cairano, Giovanna Finzi, Carlo Capella, Fausto Sessa et al. · 2014 · American Journal Of Pathology
Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients
Chia‐Hsuin Chang, Jou‐Wei Lin, Shu‐Ting Chen, Mei‐Shu Lai, Lee‐Ming Chuang, Yi‐Cheng Chang · 2016 · Medicine
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, Adina Frum, Adriana Aurelia Chiş, Luca Liviu Rus, Stéliana Ghibu, Anca Maria Juncan, Andrei Cătălin Muntean, Antonina Evelina Lazăr et al. · 2024 · Biomedicines
Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
Stephano Cedirian, Monia Donati, Luca Rapparini, Francesca Pampaloni, M. La Plaça, Rossella Sgarzani, Luca Negosanti, Emanuel Raschi, Michela Valeria Rita Starace · 2025 · Dermatology and Therapy
Adverse Effects Associated With Newer Diabetes Therapies
Oluwaranti Akiyode, Adebola A. Adesoye · 2015 · Journal of Pharmacy Practice
Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity score-matched study with competing risk analysis
Oscar Hou In Chou, Jiandong Zhou, Jonathan V Mui, Danish Iltaf Satti, Cheuk To Chung, Teddy Tai Loy Lee, Sharen Lee, Edward Christopher Dee, Kenrick Ng, Bernard M.Y. Cheung et al. · 2022 · Diabetes Epidemiology and Management
Something old, something new and something very old: drugs for treating type 2 diabetes
Diana Kaiser, Elke Oetjen · 2014 · British Journal of Pharmacology
Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
Jocelyn de Heer, Burkhard Göke · 2014 · Expert Opinion on Drug Safety
Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice
Aaron R. Cox, Carol J. Lam, Matthew M. Rankin, Jacqueline S. Rios, Julia Chavez, Claire W. Bonnyman, Kourtney B. King, Roger A. Wells, Deepti Anthony, Justin X. Tu et al. · 2017 · Endocrinology
Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER
Véronique Gigoux, Daniel Fourmy · 2013 · Frontiers in Endocrinology
Incretins and risk of neoplasia
Thorvardur Ragnar Halfdanarson, Rahul Pannala · 2013 · BMJ
Glucagon-Like Peptide 1–Based Therapies and Risk of Pancreatic Cancer in Patients With Diabetes and Obesity
Arunkumar Krishnan, Yousaf Bashir Hadi, William R. Hutson, Shyam J Thakkar, Shailendra Pratap Singh · 2022 · Pancreas
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin‐based therapies
Sandra Ueberberg, Hendrik Jütte, Waldemar H. Uhl, Wolfgang Ekkehard Schmidt, Michael Albrecht Nauck, Eduard Montanya, Andrea Tannapfel, Juris Jendrik Meier · 2016 · Diabetes Obesity and Metabolism
Islet cell dysfunction in patients with chronic pancreatitis
Ayan Roy, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Dukhabandhu Naik, Pazhanivel Mohan, Biju Pottakkat · 2020 · World Journal of Diabetes
Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?
Belinda Gier, Peter C. Butler · 2013 · JAMA Internal Medicine
GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies
John A. Williams · 2015 · Pancreatology
Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice
Hongjun Deng, Fengying Yang, Xiaoyi Ma, Ying Wang, Qi Chen, Yuan Li · 2020 · Cell Transplantation
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Richard E. Pratley, Zeb Ijaz Saeed, Anna Casu · 2024 · Current Opinion in Gastroenterology
Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials
Adili Tuersun, Guanxin Hou, Gang Cheng · 2024 · Clinical Therapeutics
Fighting Type-2 Diabetes: Present and Future Perspectives
Cai‐Guo Yu, Ying Fu, Yuan Fang, Ning Zhang, Rongxin Sun, Dong Zhao, Yingmei Feng, Baoyu Zhang · 2017 · Current Medicinal Chemistry
Glucagon-like Peptide-1 Receptor Agonists
Ja Young Jeon, Hae Jin Kim · 2021 · Stroke revisited
Incretins and the intensivist: what are they and what does an intensivist need to know about them?
Mark Philip Plummer, Marianne J. Chapman, Michael Horowitz, Adam M. Deane · 2014 · Critical Care
Risk of all–cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network
Enrico Tartaglia, Tommaso Bucci, Michele Rossi, Andrea Galeazzo Rigutini, Amir Askarinejad, Uazman Alam, Katarzyna Nabrdalik, Giuseppe Boriani, Gregory Y.H. Lip · 2025 · Cardiovascular Diabetology
Exploring the potential impact of GLP-1 receptor agonists in cancer therapy
Baseer Aslam, Muhammad Daim Bin Zafar, Mah I Kan Changez, Muhammad ABDULLAH, Muhammad Safwan, Bisma QAMAR, Abdullah SHINWARI, Sanjana RAI · 2023 · Minerva Endocrinology
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
Edoardo Mannucci, Ilaria Dicembrini · 2026 · Nature Reviews Clinical Oncology
The glucagon‐like peptide‐1‐based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys
Denis Roy, Kristina D. Chadwick, Krystyna Tatarkiewicz, Carl LaCerte, Ann‐Marie Bergholm, Thomas Brodie, Raja S. Mangipudy, David G. Parkes, Michael J. Graziano, Tim Reilly · 2014 · Diabetes Obesity and Metabolism
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
Abul B. M. Kamrul-Hasan, Sunetra Mondal, Deep Dutta, Lakshmi Nagendra, Mohammed Ruhul Kabir, Joseph M Pappachan · 2024 · Obesity Science & Practice
Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer
Ana Inés Cases, Takao Ohtsuka, Hideyo Kimura, BIAO ZHENG, Koji Shindo, Yoshinao Oda, Kazuhiro Mizumoto, Masafumi Nakamura, Masao Tanaka · 2015 · Oncology Reports
A synopsis of factors regulating beta cell development and beta cell mass
Krishna L. Prasadan, Chiyo Shiota, Xiangwei Xiao, David Matthew Ricks, Joseph C. Fusco, George K. Gittes · 2016 · Cellular and Molecular Life Sciences
GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
Michael Goggins · 2012 · Diabetes
Incretin-mimetics associated pancreatitis: evidence from the spontaneous adverse drug reactions reporting in Italy
Marcello Delfino, Domenico Motola, Angela Benini, Gian Pietro Franzè, Marcella Barotto, Anna Campi, Vincenzo Maria Monda · 2013 · Expert Opinion on Drug Safety
Gene expression signature: a powerful approach for drug discovery in diabetes
Smithamol Sithara, Tamsyn M. Crowley, Ken R. Walder, Kathryn Aston‐Mourney · 2016 · Journal of Endocrinology
Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database
Davide Soranna, Cristina Bosetti, Manuela Casula, Elena Tragni, Alberico Luigi Catapano, Carlo La Vecchia, Luca Giuseppe Merlino, Giovanni Corrao · 2015 · Diabetes Research and Clinical Practice
An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks
Amy L. Usborne, Richard A. Byrd, James Meehan, Jamie L. Blackbourne, John Sullivan, Florence Poitout‐Belissent, Annick Préfontaine, Jennifer A. Martin, John L. Vahle · 2015 · Toxicologic Pathology
Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604
Robert J. Heine, Haoda Fu, David M. Kendall, David E. Moller · 2013 · Diabetes
Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604
Alexandra E. Butler, Martha Campbell‐Thompson, Tatyana Gurlo, David W. Dawson, Mark A. Atkinson, Peter C. Butler · 2013 · Diabetes
Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis
Yuxiang Lin, Guangyong Xu, Liangyu Li, Jingyi Xiang, Lingyun Zhai · 2024 · Medicine
Incretin Therapy and Pancreatic Pathologies: Background Pathology Versus Drug-Induced Pathology in Rats
Josephine Mary Egan, Chee W. Chia · 2014 · Diabetes
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
Lee, Hae Young, Ko, Seung-Hyun, Park, Sungjoon, Kim, Kyuho, Kim, Song-Yi, Cho, In-Jeong, Cho, Eun Joo, Kim, Hyeon Chang, Park, Jae-Hyeong, Ryu, Sung Kee et al. · 2024 · Clinical Hypertension
Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients
Katarzyna Wawrzak-Pienkowska, Tomasz Pienkowski, Aleksandra Golonko, Anna Krupa, Marcin Warpechowski, Adam Filip Płoński, Patrycja Mojsak, Jarosław Daniluk, A Dâbrowski, Krzysztof Kurek · 2025 · European Journal of Pharmacology
Dose-dependent pancreatitis risk associated with GLP-1 agonists
Joyce Hanyue Gu, Mark Samarneh · 2025 · Journal of Diabetes & Metabolic Disorders
Risk Factors for Pancreatic Ductal Adenocarcinoma Specifically Stimulate Pancreatic Duct Glands in Mice
Alexej Bobrowski, Marie Spitzner, Stefanie Bethge, Fabian Müller‐Graf, Brigitte Vollmar, Dietmar Zechner · 2013 · American Journal Of Pathology
Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis
Mahmoud Nassar, Hazem Maarouf Abosheaishaa, Anoop Misra, Paresh Dandona, Husam Ghanim, Ajay Chaudhuri · 2025 · Diabetes & Metabolism
Exendin-4 impairs the autophagic flux to induce apoptosis in pancreatic acinar AR42J cells by down-regulating LAMP-2
Zhiqiang Li, Shaihong Zhu, Lihua Huang, Mingming Shang, Can Yu, Hongwei Zhu, Duo Han, Hui Huang, Xiao Yu, Xia Li · 2018 · Biochemical and Biophysical Research Communications
Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys
John L. Vahle, Richard A. Byrd, Jamie L. Blackbourne, Jennifer A. Martin, Steven D. Sorden, Thomas E. Ryan, Thomas P. Pienkowski, Thomas J. Rosol, Paul W. Snyder, Günter Klöppel · 2015 · Toxicologic Pathology
Extended Exenatide Administration Enhances Lipid Metabolism and Exacerbates Pancreatic Injury in Mice on a High Fat, High Carbohydrate Diet
Rodney L. Rouse, Leshuai W. Zhang, Katherine I Shea, Hongfei Zhou, Lin Xu, Sharron R. Stewart, Barry A. Rosenzweig, Jun Zhang · 2014 · PLoS ONE
Approach to the Patient With Pancreatogenic Diabetes
Katie Larson Ode, Yumi Imai, Andrew W. Norris · 2025 · The Journal of Clinical Endocrinology & Metabolism
A systematic review of the safety of incretin-based therapies in type 2 diabetes
Marc Evans, Stephen Charles Bain, Jiten P Vora · 2016 · Expert Review of Endocrinology & Metabolism
Does the use of incretin‐based medications increase the risk of cancer in patients with type‐2 diabetes mellitus?
Igor Karp, Atul Sivaswamy, Christopher M. Booth · 2019 · Pharmacoepidemiology and Drug Safety
Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide
Xinyi He, Zimo Zhao, Yan Sun, Xi Jiang · 2025 · European Journal of Medicinal Chemistry
Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues
Marco Dal Molin, Haeryoung Kim, Amanda L. Blackford, Rajni B Sharma, Michael Goggins · 2015 · Pancreas
The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
Zhiyuan Cheng, Shuang Wang, Fu‐Rong Li, Cheng Jin, Chunbao Mo, Jing Zheng, Xia Li, Fengchao Liang, Jin-Kui Yang, Dongfeng Gu · 2024 · Journal of Diabetes
Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials
Edwin AM Gale · 2015 · Diabetes Care
The Effects of Dipeptidyl-Peptidase-IV Inhibitor, Vildagliptin, on the Exocrine Pancreas in Spontaneously Diabetic Goto-Kakizaki Rats
Hiroki Mizukami, Wataru Inaba, Kazunori Takahashi, Kosuke Kamata, Kentaro Tsuboi, Soroku Yagihashi · 2013 · Pancreas
Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber, Carol Wysham · 2012 · Endocrine Practice
The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients
Zeynel Abidin Sayıner, Gamze İnan Demiroğlu, Ersin Akarsu, Mustafa Araz · 2018 · Turkish Journal of Pharmaceutical Sciences
Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
Marion L. Vetter, Kristina M. Johnsson, Elise Hardy, Hui Wang, Nayyar Iqbal · 2019 · Diabetes Therapy
Acute Pancreatitis Induced by Linagliptin: A Rare but Dangerous Side Effect
Artem Sharko, Shirly Samuel, Nikita Jain · 2021 · Cureus
In the setting of β-cell stress, the pancreatic duct gland transcriptome shows characteristics of an activated regenerative response
Alexandra E. Butler, David Kirakossian, Tatyana Gurlo, Fuying Gao, Giovanni Coppola, Peter C. Butler · 2018 · American Journal of Physiology-Gastrointestinal and Liver Physiology
Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities
Galyna V. Graham, John Michael Conlon, Yasser H.A. Abdel‐Wahab, Peter R. Flatt · 2020 · European Journal of Pharmacology
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Silvio E Inzucchi, Aldo J. Peixoto, Jeffrey M Testani · 2021 · New England Journal of Medicine
A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways
Christine Park, Yushin Kim, Sawye Raygani, Eduardo L. Grunvald · 2025 · Frontiers in Endocrinology
Τhiazolidine-4-One Derivatives with Variable Modes of Inhibitory Action Against DPP4, a Drug Target with Multiple Activities and Established Role in Diabetes Mellitus Type II
Dionysia Amanatidou, Phaedra T. Eleftheriou, Anthi Petrou, Athina A. Geronikaki, Theodore S. Lialiaris · 2025 · Pharmaceuticals
Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?
Jens Juul Holst · 2013 · Diabetologia
GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis
Sean M. Brady, Michael P. Kane, Robert S. Busch · 2015 · AACE Clinical Case Reports
Glucagon‐like peptide‐1 receptor agonist exenatide has no acute effect on MRI ‐measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial
Mark M. Smits, Lennart Tonneijck, Marcel H.A. Muskiet, Mark H.H. Kramer, Michaëla Diamant, Indra C. Pieters-van den Bos, Daniël H. van Raalte, Djuna L. Cahen · 2015 · Diabetes Obesity and Metabolism
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Emi Kawakita, Keizo Kanasaki · 2024 · Journal of Diabetes Investigation
Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist
Hae Jin Kim · 2021 · Journal of Korean Diabetes
Uncovering the mechanisms of beta-cell neogenesis and maturation toward development of a regenerative therapy for diabetes
Takeshi Miyatsuka · 2015 · Diabetology International
GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades
Hirofumi Watanabe, Fumiyoshi Fujishima, Yuto Yamazaki, Masayuki Imamura, Susumu Hijioka, Kazuo Hara, Takamichi Kuwahara, Yasushi Yatabe, Kazuhiro Sakamoto, Hisashi Shiga et al. · 2025 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Incretin-based therapies and pancreatitis risk: myth or reality
Joseph M Pappachan · 2014 · Endocrine
Exenatide Induces Impairment of Autophagy Flux to Damage Rat Pancreas
Zhiqiang Li, Lihua Huang, Xiao Yu, Can Yu, Hongwei Zhu, Xia Li, Duo Han, Hui Huang · 2016 · Pancreas
Exploring the GLP-1–GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
Elin Manell, Emmi Puuvuori, Anna Christina Svensson, Irina Velikyan, Gry Hulsart‐Billström, Patricia Hedenqvist, Jens Juul Holst, Marianne Jensen‐Waern, Olof Eriksson · 2021 · BMJ Open Diabetes Research & Care
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
Conor F. Murphy, Carel Wynand le Roux · 2018 · Annals of Translational Medicine
Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
Roger R. C. New, Michal Bogus, G. N. Travers, U. Hahn, Agne Vaiceliunaite, Michael W. M. Burnet, J. H. Wang, H. Wen · 2024 · Frontiers in Drug Delivery
Disproportionality analysis of GLP-1 receptor agonists combined with metformin based on the FAERS database
Boyi Liu, Ruizhe Huang, Wenchao Zhang, J H Tian, Yao Xian, Danna Chen · 2025 · Scientific Reports
Acute pancreatitis and euglycemic non-diabetic ketoacidosis caused by an intentional semaglutide overdose
Anthony Acosta, Ashley Fanco, H P Rohan, Zane Z. Elfessi · 2025 · JEM Reports
Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats
Elina Akalestou, Ioannis A. Christakis, Antonia Solomou, JAMES S. MINNION, Guy A. Rutter, Stephen Robert Bloom · 2016 · Pancreas
Exocrine and Endocrine Inflammation Increases Cellular Replication in the Pancreatic Duct Compartment in Type 1 Diabetes
Shweta Kulkarni, Amanda L. Posgai, Irina Kusmartseva, Clive Henry Wasserfall, Mark A. Atkinson, Alexandra E. Butler · 2022 · Journal of the Endocrine Society